Literature DB >> 12678793

Cationic lipid vectors for plasmid DNA delivery.

Aaron Hirko1, Fuxing Tang, Jeffrey A Hughes.   

Abstract

Successful gene therapy depends on efficient gene transfer vectors. Viral vectors and non-viral vectors have been investigated extensively. Cationic lipids are non-viral vectors, which resemble traditional pharmaceuticals, display little immunogenicity, and have no potential for viral infection. However, toxicity and low transfection efficiency are two barriers limiting the clinical applications of cationic lipids. Over the last decade, hundreds of cationic lipids have been synthesized to address these problems. In this brief review, we summarized recent research results concerning the structures of DNA/liposomes complexes, some important strategies used to design different classes of cationic lipids, and use of disulfide cationic lipids in plasmid DNA delivery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12678793     DOI: 10.2174/0929867033457412

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  18 in total

1.  Transfection of living HeLa cells with fluorescent poly-cytosine encapsulated Ag nanoclusters.

Authors:  Yasuko Antoku; Jun-ichi Hotta; Hideaki Mizuno; Robert M Dickson; Johan Hofkens; Tom Vosch
Journal:  Photochem Photobiol Sci       Date:  2010-03-22       Impact factor: 3.982

2.  Construction and identification of Fas-targeting siRNA-expressing plasmid.

Authors:  Su-hu Liu; Wang-gang Zhang; Mei Zhang; Qing Zhu; Wei Tian
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

3.  Cationic liposome-microtubule complexes: pathways to the formation of two-state lipid-protein nanotubes with open or closed ends.

Authors:  Uri Raviv; Daniel J Needleman; Youli Li; Herbert P Miller; Leslie Wilson; Cyrus R Safinya
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-29       Impact factor: 11.205

4.  Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2013-09-17

Review 5.  From serendipity to mitochondria-targeted nanocarriers.

Authors:  Volkmar Weissig
Journal:  Pharm Res       Date:  2011-08-11       Impact factor: 4.200

Review 6.  Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9.

Authors:  Hong-Xia Zhang; Ying Zhang; Hao Yin
Journal:  Mol Ther       Date:  2019-01-25       Impact factor: 11.454

7.  Lipid nanoparticle delivery systems for siRNA-based therapeutics.

Authors:  C Wan; T M Allen; P R Cullis
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

8.  Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.

Authors:  Li Pan; Xing-Chen Peng; Fei Leng; Qing-Zhong Yuan; Yan Shan; Dan-Dan Yu; Zhi-Yong Li; Xiang Chen; Wen-Jing Xiao; Yuan Wen; Tian-Tai Ma; Li Yang; Yong-Qiu Mao; Han-Shuo Yang; Yu-Quan Wei; Chun-Ting Wang
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

9.  Novel cationic lipids with enhanced gene delivery and antimicrobial activity.

Authors:  David E Fein; Robert Bucki; Fitzroy Byfield; Katarzyna Leszczynska; Paul A Janmey; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-06-23       Impact factor: 4.436

10.  Effects of PI3-k/Akt short hairpin RNA on proliferation, fibronectin production and synthesis of thrombospondin-1 and transforming growth factor-beta1 in glomerular mesangial cells induced by sublytic C5b-9 complexes.

Authors:  L Gao; Y Zhang; W Qiu; W Xu; X Feng; J Ren; X Jiang; H Wang; D Zhao; Y Wang
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.